The U.S. Food and Drug Administration (FDA) announced the marketing authorization for ophthalmic lenses, becoming the first frame lenses designed not only to correct myopia in children, with or without astigmatism, but also to slow the progression of this condition at early ages, between 6 and 12 years at the start of treatment.

This decision represents a significant advance in pediatric eye care, as until now the only approved option for this purpose were contact lenses intended for children ages 8 to 12, leaving no alternative for the youngest children or those unable to wear contact lenses.

The authorization is based on growing global concern about the rapid increase in myopia.

WHOM DOES IT IMPACT?

The direct impact is on children between 6 and 12 years of age with myopia, with or without astigmatism, eye care professionals, healthcare systems, and manufacturers.

CONCLUSION:

This approval marks a momentous advance in pediatric ophthalmology, offering an innovative and safe solution that not only corrects vision but also reduces the likelihood of severe vision complications in adulthood, contributing to improved long-term eye health.